Research Paper Volume 11, Issue 15 pp 5744—5756

miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN

Figure 5. MiR-627-3p suppresses HOS cell proliferation and migration by targeting PTN. (A) MTT assays showing the effects of miR-627-3p inhibitor and PTN siRNA on cell proliferation. Data are the mean ± SEM. ** P< 0.05, control vs miR-627-3p inhibitor/si-PTN; ^^P< 0.05, miR-627-3p inhibitor vs si-PTN. (B) Transwell assays showing the effects of miR-627-3p inhibitor and PTN siRNA on cell metastasis. Cells were counted, and results represent the mean ± SD of three experiments. ** P< 0.05, control vs miR-627-3p inhibitor/si-PTN; ^^P< 0.05 miR-627-3p inhibitor vs si-PTN. (C, D) Western blot and real-time PCR analysis of the effects of miR-627-3p inhibitor and PTN siRNA on expression of PTN, Cyclin D1 and MMP2. Data are the mean ± SEM. ** P< 0.05, control vs miR-627-3p inhibitor/si-PTN; P< 0.05 miR-627-3p inhibitor vs si-PTN. (E) MTT assays showing the effects of miR-627-3p and PTN on cell proliferation. Data are the mean ± SEM. ** P< 0.05, control vs miR-627-3p/PTN; ^^P< 0.05 miR-627-3p vs PTN. (F) Transwell assays showing the effects of miR-627-3p and PTN on cell metastasis. Shown are counts of migrated cells. Results represent the mean ± SD of three experiments. **P< 0.05, control vs miR-627-3p/PTN; ^^P< 0.05, miR-627-3p vs PTN. (G, H) Western blot and real-time PCR analysis of the effects of miR-627-3p and PTN on PTN, Cyclin D1 and MMP2 expression. Data are the mean ± SEM. ** P< 0.05, control vs miR-627-3p/PTN; ^^P< 0.05 miR-627-3p vs PTN.